EUVIMEDEUVIMED entdecken
Crossref

Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications

Alberto Guijosa iD, Nickolas Tsakamaklis, Margaret Kobs, Amanda Kofides, Nina Budano, Julia Nguyen, Alexandra Eurell, Kirsten Meid, Maria Luisa Guerrera, Zachary R Hunter iD, Steven P Treon iD, Shayna Sarosiek und 1 weitere

American Journal of Hematology · 2026

DOI: 10.1002/ajh.70269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2026. Verfasst von Alberto Guijosa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Pyrimidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: American Society of Hematology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venetoclax and pirtobrutinib have emerged as two chemotherapy‐free options for relapsed or refractory Waldenström macroglobulinemia (WM). However, evidence to guide treatment sequencing or identify molecular subsets most likely to benefit from each agent remains limited. We retrospectively evaluated consecutive WM patients treated with venetoclax or pirtobrutinib. Major response rate (MRR) and progression‐free survival (PFS) were assessed for each agent, with predictors of response and PFS analyzed using logistic and Cox regression. Comparative efficacy was examined in unmatched analyses and in a 1:1 matched cohort. Among 91 treatment exposures (64 venetoclax and 27 pirtobrutinib) across 80 unique patients, treatment discontinuation due to adverse effects occurred in 12 of 64 patients (19%) treated with venetoclax and in none treated with pirtobrutinib. In the venetoclax cohort, TP53 alterations were associated with shorter PFS (10.0 vs. 35.6 months; p < 0.001). In the pirtobrutinib cohort, CXCR4 mutations predicted lower MRR (40% vs. 91%; p = 0.01) and shorter PFS (8.3 months vs. not reached; p = 0.02). When transitioning from a cBTKi, IgM rebound occurred in 62% (8/13) of patients initiating venetoclax without overlap, whereas no rebound was observed with cBTKi‐venetoclax overlap (0/5) or with pirtobrutinib initiation (0/15). In the matched cohort ( n = 42), venetoclax and pirtobrutinib demonstrated comparable outcomes for MRR ( p = 0.91) and PFS ( p = 0.83). Despite the retrospective design and limited sample size, these findings indicate comparable efficacy between venetoclax and pirtobrutinib with distinct molecular vulnerabilities and support consideration of pirtobrutinib sequencing when transitioning from a cBTKi, as well as further exploration of combination strategies that may exploit complementary vulnerabilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaSulfonamidesBridged Bicyclo Compounds, HeterocyclicPyrimidinesAntineoplastic AgentsHumansFemaleRetrospective StudiesMaleAgedAged, 80 and overMiddle AgedRecurrenceTumor Suppressor Protein p53MutationPyrazoles

Stichwörter der Autor:innen

CXCR4IgM reboundTP53Waldenström macroglobulinemiapirtobrutinibvenetoclax

Substanzen

SulfonamidesBridged Bicyclo Compounds, HeterocyclicvenetoclaxPyrimidinesTumor Suppressor Protein p53Antineoplastic AgentspirtobrutinibPyrazoles

Autor:innen und Institutionen

  • Bing Center for Waldenström's Macroglobulinemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Alberto Guijosa, Zachary R Hunter, Steven P Treon

Förderung

  • American Society of Hematology

Zitieren

APA

Guijosa, A., Tsakamaklis, N., Kobs, M., Kofides, A., Budano, N., Nguyen, J., Eurell, A., Meid, K., Guerrera, M. L., Hunter, Z. R., Treon, S. P., Sarosiek, S., & Castillo, J. J. (2026). Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. American Journal of Hematology. https://doi.org/10.1002/ajh.70269

Vancouver

Guijosa A, Tsakamaklis N, Kobs M, Kofides A, Budano N, Nguyen J, et al. Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. American Journal of Hematology. 2026. doi:10.1002/ajh.70269

BibTeX
@article{Guijosa2026,
  author = {Guijosa, Alberto and Tsakamaklis, Nickolas and Kobs, Margaret and Kofides, Amanda and Budano, Nina and Nguyen, Julia and Eurell, Alexandra and Meid, Kirsten and Guerrera, Maria Luisa and Hunter, Zachary R and Treon, Steven P and Sarosiek, Shayna and Castillo, Jorge J},
  title = {Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications},
  journal = {American Journal of Hematology},
  year = {2026},
  doi = {10.1002/ajh.70269}
}
Kostenlos starten →